Efficacy and safety of TiNO-coated stents versus drug-eluting coronary stents. Systematic literature review and meta-analysis.

Frederic C. Daoud, MD, MSc[a], Louis Létinier, MD, MSc[a], Nicholas Moore, MD, PhD[a], Pierre Coste, MD[b], Pasi P. Karjalainen, MD, PhD[c]

Short title: TiNO-coated stents *vs.* DES meta-analysis

Abstract word count: 248

Manuscript file word count: 5,396 including 1914 words in the body of the article and tables

Figures: 4

Tables: 3

Affiliations

[a] Univ. Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France

[b] Coronary Care Unit, Cardiologic Hospital, University of Bordeaux, Pessac, France

[c] Cardiac unit, Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland

Address for correspondence

Frederic C. Daoud, M.D., M.Sc.
orcid.org/0000-0002-0469-9723
Université de Bordeaux
Unité de Pharmacologie clinique
INSERM U1219 Bordeaux Population Health Center
Bâtiment 1A, 1er étage, Case 36
146 rue Léo Saignat
33076 Bordeaux Cedex, France
Tel. +33 (0)5 57 57 15 60, Fax +33 (0)5 57 57 46 71 06
E-mail: frederic.daoud-pineau@u-bordeaux.fr

Abstract

Background:

Randomized clinical trials (RCTs) comparing percutaneous coronary interventions (PCI) with titanium-nitride-oxide coated stents (TiNOS) versus drug-eluting stents (DES) in coronary artery disease (CAD) have been published.

Objectives:

To compare the efficacy and safety of PCI with TiNOS versus DES at 1 and 5-year follow-up, in all CAD including acute coronary syndrome (ACS).

Methods:

A prospective systematic literature review and meta-analysis of RCTs were conducted according to published methods (Cochrane, PRISMA, GRADE). Medline, Embase, Cochrane database, Web of Science were searched on March 08, 2018. Fixed-effects Mantel-Haenszel pooled risk ratios (RR), TiNOS over DES, with 95% confidence intervals (CI) were computed with sensitivity analysis.

Results:

Five RCTs were eligible with n = 1,855 TiNOS *vs.* n = 1,363 DES at 1-year and n = 783 *vs.* n = 771 at 5-year follow-up. One-year RRs in ACS patients: Major Adverse Cardiac Events (MACE) 0.93 [0.72, 1.20], recurrent myocardial infarction (MI) 0.42 [0.28, 0.63], probable or definite stent thrombosis (ST): 0.35 [0.20, 0.64]. Estimates were robust to sensitivity analysis. Certainty of evidence was high in MACE, moderate in MI and ST due to the limited number of cases. Data were insufficient to draw conclusions about stable CAD patients and 5-year outcomes.

Conclusions:

This meta-analysis showed in ACS patients, similar risk of MACE with TiNOS and DES, at 1-year follow-up, and suggested a lower risk of MI and ST with TiNOS than with DES. These two safety signals in MI and ST with the current use of DES require further investigations.

SLR registration: PROSPERO CRD42018090622
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=90622

Keywords

TiNOS; titanium nitride oxide coated stent; DES; systematic literature review; meta-analysis

63

64 **Background**

65 Clinical evidence has led practice guidelines to establish percutaneous coronary interventions
66 (PCI) with drug-eluting stents (DES) as the standard of care in all Coronary Artery Disease
67 (CAD) including Acute Coronary Syndrome (ACS).[1-6] The trade-off is the prolongation of dual
68 antiplatelet therapy (DAPT).[7,8]

69 The two main types of eluted drugs used so far have been rapamycin-analogs such as sirolimus,
70 and paclitaxel. These drugs share the common purpose of mitigating post-stenting restenosis.[9-11]
71 Titanium-nitride-oxide coated coronary stents (TiNOS), also designated "bioactive stents" (BAS)
72 have a pharmacologically inactive, non-absorbable coating and one preclinical study has shown
73 less neointimal hyperplasia with that coating than with bare-metal stents (BMS).[12,13,14]

74

75 **Objectives**

76 The systematic literature review (SLR) is the first to compare the efficacy and safety of TiNOS
77 *vs.* DES in CAD. The question was specified using the PICOS framework[15]:

78 **P**atients presented CAD including ACS. **I**ntervention was PCI using TiNOS and the **C**omparator
79 was PCI using DES. **O**utcomes were device-oriented Major Adverse Cardiac Events (device-
80 oriented MACE), recurrent myocardial infarction (MI), stent thrombosis (ST), and all-cause
81 mortality ("total death": TD) at 1-year and 5-year follow-up. **S**tudy methods were randomized
82 controlled clinical trials (RCTs).

83

84 **Methods**

85 This SLR was designed and conducted according to methods described in the Cochrane
86 Handbook with the use of "Grading of Recommendations Assessment, Development and

87 Evaluation" (GRADE), and is reported according to "Preferred Reporting Items for Systematic
88 Reviews and Meta-Analyses" (PRISMA).[16-18]
89 The protocol was developed prospectively and registered in PROSPERO (CRD42018090622).
90 Data recording and the meta-analysis were conducted in RevMan 5.3 (Review Manager Version
91 5.3 software. Copenhagen, Denmark: The Nordic Cochrane Centre, 2014). The certainty of
92 evidence according to GRADE was rated with GRADEpro GDT software 2020 on-line version,
93 (https://gradepro.org). Additional analyses and cross-checks were performed in STATA 16
94 (StataCorp LP, College Station, Tx, USA) using the metan and metaprop packages.
95 MEDLINE, EMBASE, the Cochrane Library, and Web of Science electronic databases, were
96 queried on March 08 2018 using their own search engines. The search terms were: *((bioactive*
97 *OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR*
98 *(drug AND eluting AND stent)) AND (RCT OR ((randomized OR randomised) AND controlled*
99 *AND trial))*. No exclusion filter was applied related to language, country, year, or any other
100 aspect. The websites of AHA, TCT, ESC, EuroPCR, and clinicaltrials.gov were also searched.
101 The queries were updated on July 22 2020 when all initially identified RCTs were published to
102 retrieve new evidence if any, from RCTs meeting the PICOS specifications of this SLR.
103 The downloaded record files were imported and pooled and sifted in EndNote X8 (Clarivate
104 Analytics, Philadelphia, PA, USA). When duplicates were identified, only one version was kept.
105 When several references concerned the same study, their information was pooled using the
106 citation of the most recent one. Full articles were reviewed for all references.
107 Two reviewers (FD and LL) performed separately and in parallel, all the following steps:
108 screened all references, classified them according to the review protocol's inclusion and

exclusion criteria, extracted the characteristics and relevant data of each RCT into RevMan 5.3 tables, rated the risk of bias of individual RCTs, assessed each outcome per GRADE. Results were then reconciled and disagreements were resolved by consensus after discussion with a third reviewer (NM). The similarity of the definitions of endpoints used across the RCTs and the ability to pool results was discussed with one investigator (PK). The risk of bias of individual RCTs was rated according to the criteria proposed by the Cochrane Collaboration with operator blinding as a separate item and the certainty of pooled evidence for each outcome variable was rated according to GRADE. Study publications were included if they met the following criteria: First-hand clinical evidence with prospective inclusion; patients with CAD treated with coronary PCI; implantation of either TiNOS or DES after random allocation; target outcomes reported at 1-year and/or 5-year follow-up; outcomes reported as the number of patients with an event or their rate along with the corresponding sample size.

References were ruled out if any of the above criteria were not met or if they did not report IRB/ethics committee approval and patient informed consent.

The primary outcome was device-oriented MACE at 12-month follow-up and the secondary outcomes were MI, probable or definite ST, and TD.

All definitions were those of the Academic Research Consortium (ARC) 2007.[19] Device-oriented MACE was the composite of Cardiac death (CD), Myocardial Infarction (MI) not attributable to a non-target vessel, repeat Target Lesion Revascularization (TLR) driven by recurrent myocardial ischemia.[1] The secondary outcome variables were the same at 5-year follow-up. All outcomes were analyzed with stratification on ACS and other CAD.

The two treatment arms were compared for each endpoint using the risk ratio (RR) defined as *((n patients with an event in TiNOS)/(n patients in TiNOS))/((n patients with an event in DES)/(n*

132 *patients in DES))*. As a result, if the frequency of events was greater in TiNOS than in DES, then
133 the RR would be greater than 1 and conversely. The analysis was performed according to the
134 intention-to-treat (ITT) method where a patient presenting an event was counted in the treatment
135 arm he/she had been randomized to and where the denominator was the number of patients
136 randomized to the corresponding arm.
137 Individual study and pooled RR with 95% confidence interval (CI [,]) were calculated. Pooling
138 used the Mantel-Haenszel (M-H) fixed-effect model if no significant heterogeneity between the
139 RRs of individual RCTs was detected, and the M-H random-effects model otherwise.[16,20,21]
140

141 **Results**

142 The study identification and selection processes after the initial extraction were described in a
143 PRISMA flowchart (Figure 1). Overall, 111 references were identified and screening resulted in
144 8 publications and 1 presentation (the TIDES-ACS trial) with first-hand data concerning 5 RCTs,
145 all of which were included in the meta-analysis.
146 The number of patients at baseline and at 1-year follow-up was n = 2,951 with n = 1,855 in the
147 TiNOS arm and n = 1,363 in the DES arm. The number who had reached 5-year follow-up was n
148 = 783 (TiNOS) and n = 773 (DES). Two RCTs (TIDE and TITANIC-XV) combined patients
149 with ACS and other CAD without reporting outcomes separately for those two subgroups, while
150 the three others included patients with ACS only (TITAX-AMI, BASE-ACS, and TIDES-ACS).
151 The baseline characteristics are summarized in Table 1. Funnel plots and Harbord tests did not
152 detect a risk of publication bias.
153 The risk of bias in individual RCTs was low or moderate in all RCTs except for the operator's
154 knowledge of the type of stent during the intervention.

155 The pooled RRs of all outcomes at 1-year and 5-year follow-ups, in all CAD and the ACS
156 subgroup, along with sensitivity analysis are reported in Table 2. The number of studies and
157 events is insufficient to conclude about 5-year outcomes.
158 The stratified Forrest plots (ACS *vs.* other CAD) with heterogeneity analysis show no significant
159 difference in 1-year MACE between TiNOS and DES, but show significantly lower rates of
160 recurrent MI and ST with TiNOS compared to DES (Figure 2 to Figure 4). Effect size and
161 robustness to sensitivity analysis in recurrent MI and ST found in all CAD are driven by the
162 results in the ACS subgroup.
163 Stratified analysis showed a relatively low number of patients with "other CAD" stratum
164 compared to the ACS (14.8% versus 85.2% among 3,218 patients, Figure 2) and significant
165 heterogeneity between the strata ($p = 0.05$, $I^2 = 73.4\%$, Figure 2). This leads reviewers to narrow
166 down the scope of the subsequent steps of this SLR to 1-year outcomes in ACS only.
167
168 **Results in ACS at 1-year follow-up**
169 The pooled RR of MACE is non-significant 0.93 [0.72, 1.20], without significant heterogeneity
170 between studies ($I^2 = 0\%$) (Figure 2) and is robust to sensitivity analysis (Table 2). The Optimal
171 Information Size (OIS) criterion is met, the number of cases that would need to be shifted from
172 the DES arm to the TiNOS arm in a simulation is close to 2.7 times the non-inferiority margin,
173 and no publication bias is detected. The certainty of the evidence according to GRADE is
174 therefore rated high (Table 3).
175 The pooled RR of recurrent MI is significant 0.33 [0.22, 0.51] without significant heterogeneity
176 ($I^2 = 0\%$) (Figure 3), is robust to sensitivity analysis. However, given the OIS criterion is not met
177 and the number of events is well below the n = 300 rule of thumb, this RR presents

178 imprecision/fragility. Considering no publication bias is detected, the certainty of the evidence
179 according to GRADE is rated moderate.
180 The pooled RR of ST in ACS at 1-year follow-up is significant 0.35 [0.20, 0.64] without
181 significant heterogeneity ($I^2 = 0\%$) (Figure 4), is robust to sensitivity analysis. Given the OIS
182 criterion is not met and the number of events is well below the n = 300 rule of thumb, this RR
183 presents imprecision/fragility. Considering no publication bias is detected, the certainty of the
184 evidence is rated moderate.
185 The pooled RR of TD in ACS at 1-year follow-up is not significant 0.78 [0.47, 1.27], with
186 significant heterogeneity between RCTs ($I^2 = 66\%$), presents imprecision/fragility due to
187 insufficient amount of information (the OIS criterion is not met and the number of events being
188 well below the n = 300 rule of thumb), and a lack of robustness to sensitivity analysis.
189 Considering no publication bias is detected, the certainty of the evidence is rated low.
190

191 **Discussion**

192 The strengths of this SLR are the low risk of publication bias and the robustness of the sensitivity
193 analysis of all outcomes at 1- year except for TD. Given the certainty of evidence per GRADE,
194 the results are considered valid.
195 The main weaknesses are the low number of studies and patients, especially in CAD other than
196 ACS, and at 5-year follow-up. Additional 5-year data will be pooled when TIDE-ACS final
197 results are published. Another relative weakness is the pooling of different generations of TiNOS
198 and DES in ACS, especially paclitaxel-eluting stainless steel stents with everolimus-eluting
199 stents with cobalt-chromium or platinum-chromium platforms. Indeed, the 3 ACS RCTs show no
200 or minor-only heterogeneity (i.e. 95% CIs overlap or their edges touch) among the DES groups

201 and the TiNOS groups, respectively, in terms of 1-year incidence rates of MACE, recurrent MI,
202 and ST. Published RCTs so far comparing paclitaxel-DES and other DES have not shown
203 significant differences in STEMI or NSTEMI, whereas paclitaxel-DES have been demonstrated
204 to be inferior in other indications than ACS.
205
206 **Conclusions**
207 This systematic literature review shows that titanium-nitride oxide coated-coronary stents and
208 drug-eluting stents have a similar risk of major adverse cardiac events at one 1-year follow-up
209 when used in acute coronary syndrome. This result is robust and the level of certainty of this
210 conclusion is high.
211 It also suggests a lower risk of recurrent myocardial infarction and stent thrombosis with
212 titanium-nitride oxide coated-coronary stents than with drug-eluting stents. The size of the
213 pooled risk ratios and the robustness to sensitivity analysis are safety signals concerning the use
214 of drug-eluting stents when compared to titanium-nitride oxide coated-coronary stents in acute
215 coronary syndrome. This requires further investigation.
216 The evidence is insufficient to conclude about outcomes at five-year follow-up and in patients
217 with chronic coronary artery syndromes.
218

219

220 **Supplemental material:**

221 - Details of methods applied in this SLR.

222 - Methods of individual RCTs

223 - Table of the number of patients with events – ITT

224 - Funnel plots and results of Harbord tests.

225 - Summary of risk of bias in individual RCTs

226 - Pooled results of TD

227 - Notes of GRADE analysis

228 - Heterogeneity analysis of event incidence rates among DES and TiNOS arms.

229 - PRISMA checklist

230

231

232 **Figure 1 PRISMA flowchart**



233

234

235

236 **Figure 2 MACE at 1-year – pooled and stratified**

Study or Subgroup	TiNOS Events	TiNOS Total	DES Events	DES Total	Weight	Risk Ratio M-H, Fixed, 95% CI
5.17.1 ACS						
BASE-ACS	40	417	37	410	27.5%	1.06 [0.69, 1.63]
TIDES-ACS	62	989	35	502	34.2%	0.90 [0.60, 1.34]
TITAX-AMI	22	214	27	211	20.0%	0.80 [0.47, 1.36]
Subtotal (95% CI)		**1620**		**1123**	**81.6%**	**0.93 [0.72, 1.20]**
Total events	124		99			
Heterogeneity: Chi² = 0.70, df = 2 (P = 0.71); I² = 0%						
Test for overall effect: Z = 0.55 (P = 0.58)						
5.17.2 Other CAD						
TIDE	27	152	21	150	15.6%	1.27 [0.75, 2.14]
TITANIC-XV	12	83	4	90	2.8%	3.25 [1.09, 9.69]
Subtotal (95% CI)		**235**		**240**	**18.4%**	**1.57 [0.99, 2.51]**
Total events	39		25			
Heterogeneity: Chi² = 2.35, df = 1 (P = 0.13); I² = 57%						
Test for overall effect: Z = 1.91 (P = 0.06)						
Total (95% CI)		**1855**		**1363**	**100.0%**	**1.05 [0.84, 1.31]**
Total events	163		124			
Heterogeneity: Chi² = 6.18, df = 4 (P = 0.19); I² = 35%						
Test for overall effect: Z = 0.42 (P = 0.67)						
Test for subgroup differences: Chi² = 3.76, df = 1 (P = 0.05), I² = 73.4%						



237

238

239

240 **Figure 3 MI at 1-year – pooled and stratified**



241

242

243

244 **Figure 4 ST at 1-year – pooled and stratified**

Study or Subgroup	TiNOS Events	TiNOS Total	DES Events	DES Total	Weight	Risk Ratio M-H, Fixed, 95% CI	Year
5.19.1 ACS							
TITAX-AMI	1	214	8	211	21.1%	0.12 [0.02, 0.98]	2008
BASE-ACS	5	417	11	410	29.0%	0.45 [0.16, 1.27]	2012
TIDES-ACS	11	989	14	502	48.6%	0.40 [0.18, 0.87]	2017
Subtotal (95% CI)		**1620**		**1123**	**98.7%**	**0.35 [0.20, 0.64]**	
Total events	17		33				
Heterogeneity: Chi² = 1.28, df = 2 (P = 0.53); I² = 0%							
Test for overall effect: Z = 3.41 (P = 0.0006)							
5.19.2 Other CAD							
TITANIC-XV	0	83	0	90		Not estimable	2011
TIDE	1	152	0	150	1.3%	2.96 [0.12, 72.11]	2011
Subtotal (95% CI)		**235**		**240**	**1.3%**	**2.96 [0.12, 72.11]**	
Total events	1		0				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.67 (P = 0.51)							
Total (95% CI)		**1855**		**1363**	**100.0%**	**0.39 [0.22, 0.69]**	
Total events	18		33				
Heterogeneity: Chi² = 2.81, df = 3 (P = 0.42); I² = 0%							
Test for overall effect: Z = 3.23 (P = 0.001)							
Test for subgroup differences: Chi² = 1.64, df = 1 (P = 0.20), I² = 39.1%							



245

246

247

248 **Table 1 Baseline characteristics**

Study	**Age & prior events**			**Clinical presentation**			**Procedural data & medication**			**Attrition & cross-overs**
Stent		TiNOS	DES		TiNOS	DES		TiNOS	DES	
TITAX-AMI[22,23] [NCT00495664]	Patients n age prior MI prior PCI prior CABG	214 64±11 15% 10% 7%	211 64±11 9% 5% 6%	NSTEMI STEMI	61% 39%	54% 46%	stents in culprit lesion n TSL (mm) post-dilation procedural success DAPT 12-months	1.1±0.3 18.5±6.4 42% 99.5% 31%	1.1±0.4 19.2±7.2 35% 98.1% 65%	LFU 1y TiNOS: 0 DES: 0 5y TiNOS 3 DES: 7
TIDE[24] [NCT00492908]	Patients n age prior MI prior PCI prior CABG	152 65.9±9.0 27.6% 25.7% 7.9%	150 63.4±10.5 28.7% 21.3% 25.3% 2.7%	Stable CAD NSTEMI Unstable angina	57.9% 32.9% 9.2%	47.3% 42.0% 10.7%	stents in culprit lesion n TSL (mm) device success DAPT 12-months	1.28±0.55 19.3±11.1 93.0%	1.17±0.45 19.6±10.0 94.6%	LFU 1y TiNOS: 0 DES: 2 5y : N.R.
TITANIC-XV[25] [NCT01510509]	Patients n age prior MI prior PCI prior CABG	83 66.5±8.8 10.8% 8.4% 2.4%	90 64.5±10.1 15.6% 11.1% 2.2%	NST ACS Deducted other CAD	69.9% 30.1%	60.0% 40.0%	stents in culprit lesion n TSL (mm) stent failure DAPT 12 months	1.1±0.3 18.72±8.20 N.R.	1.1±0.3 21.63±9.65 N.R.	N.R.
BASE-ACS[26,27] [NCT00819923]	patients age prior MI prior PCI prior CABG	417 63±12 13.4% 9.6% 4.8%	410 63±12 9.8% 10.5% 4.1%	NSTEMI STEMI Unstable angina	49.4% 38.8% 11.8%	45.6% 38.8% 15.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT : Aspirin : protocol indefinite, actual N.R. Clopidogrel: protocol 6 months, actual N.R.	1.15±0.38 20.8±9.4 42.2% 0.0%	1.14±0.36 20.6±8.2 43.9% 1.0%	LFU 1y TiNOS: 3 DES: 3 5y TiNOS 29 DES: 28
TIDES-ACS[28,29] [NCT02049229]	Patients n age prior MI prior PCI prior CABG	989 62.7±10. 7.6% 7.0% 0.6%	502 62.6±10.5 9.0% 6.6% 1.2%	NSTEMI STEMI	46.3% 44.9%	45.0% 47.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT 12-months	1.13±0.38 20.5±7.8 33.0% 0.3% 80.3%	1.14±0.37 20.6±7.2 38.0% 1.0% 86.0%	LFU 1y TiNOS: 7 DES: 4

249

250

Table 2 Detailed pooled results with sensitivity analysis

M-H fixed-effects RR & 95% CI	Pooled RR with all RCTs		Sensitivity analysis: Pooled RR recalculated after removing the following RCT:				
Endpoint	Sub-group stratification	No subgroup stratification	TITAX-AMI	TIDE	TITANIC-XV	BASE-ACS	TIDES-ACS
All, MACE 1-y	1.05 [0.84, 1.31]	1.05 [0.84, 1.31]	1.11 [0.87, 1.42]	1.01 [0.79, 1.29]	0.98 [0.78, 1.24]	1.04 [0.80, 1.35]	1.13 [0.86, 1.47]
All, MACE 5-y		0.82 [0.66, 1.02]	0.91 [0.70, 1.19]	0.74 [0.58, 0.95](**)	N.A.	0.83 [0.62, 1.10]	N.A.
All, ST 1-y	0.39 [0.22, 0.69]	0.39 [0.22, 0.69]	0.46 [0.25, 0.84]	0.35 [0.20, 0.64]	0.39 [0.22, 0.69]	0.36 [0.18, 0.72]	0.38 [0.16, 0.87]
All, ST 5-y		0.25 [0.11, 0.55]	0.37 [0.14, 0.99]	0.20 [0.09, 0.49]	N.A.	0.22 [0.07, 0.70]	N.A.
All, MI 1-y	0.39 [0.27, 0.57]	0.39 [0.27, 0.57]	0.36 [0.23, 0.56]	0.34 [0.22, 0.52]	0.39 [0.26, 0.57]	0.40 [0.26, 0.63]	0.50 [0.32, 0.79]
All, MI 5-y		0.54 [0.38, 0.76]	0.59 [0.38, 0.93]	0.51 [0.35, 0.74]	N.A.	0.56 [0.33, 0.94]	N.A.
All, TD 1-y	0.78 [0.48, 1.27]	0.78 [0.48, 1.27]	0.77 [0.46, 1.32]	0.78 [0.47, 1.27]	0.78 [0.48, 1.27]	0.49 [0.26, 0.95](*)	1.22 [0.65, 2.28]
All, TD 5-y		1.03 [0.74, 1.45]	1.14 [0.75, 1.73]	0.95 [0.65, 1.37]	N.A.	1.05 [0.65, 1.69]	N.A.
ACS, MACE 1-y	0.93 [0.72 1.20]	0.93 [0.72, 1.20]	0.97 [0.73, 1.30]	N.A.	N.A.	0.86 [0.63, 1.19]	0.95 [0.68, 1.33]
ACS, MACE 5-y		0.74 [0.58, 0.95]	0.81 [0.59, 1.12](**)	N.A.	N.A.	0.65 [0.44, 0.95](**)	N.A.
ACS, ST 1-y	0.35 [0.20, 0.64]	0.35 [0.20, 0.64]	0.42 [0.22, 0.78]	N.A.	N.A.	0.32 [0.15, 0.65]	0.31 [0.12, 0.77]
ACS, ST 5-y		0.20 [0.09, 0.49]	0.28 [0.09, 0.85](**)	N.A.	N.A.	0.28 [0.09, 0.85](**)	N.A.
ACS, MI 1-y	0.33 [0.22, 0.51]	0.42 [0.28, 0.63]	0.38 [0.24, 0.62]	N.A.	N.A.	0.44 [0.27, 0.71]	0.43 [0.25, 0.74]
ACS, MI 5-y		0.51 [0.35, 0.74]	0.56 [0.33, 0.94](**)	N.A.	N.A.	0.47 [0.28, 0.79](**)	N.A.
ACS, TD 1-y	0.78 [0.47, 1.27]	0.78 [0.47, 1.27]	0.77 [0.45, 1.32]	N.A.	N.A.	0.47 [0.24, 0.93](*)	1.23 [0.64, 2.35]
ACS, TD 5-y		0.95 [0.65, 1.37]	1.02 [0.63, 1.65](**)	N.A.	N.A.	0.85 [0.48, 1.53](**)	N.A.

Notes: (*) borderline shift with 3 or fewer RCTs, (**)single-trial left N.A. Not applicable.

255

256 **Table 3 GRADE profile**

Outcome	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall certainty of evidence
MACE 1-year ACS	not serious [a]	not serious [b]	not serious [c]	not serious [d]	none detected	⊕⊕⊕⊕ HIGH
MI 1-year ACS	not serious [a]	not serious [e]	not serious [f]	serious [g]	none detected	⊕⊕⊕⊖ MODERATE
ST 1-year ACS	not serious [a]	not serious [h]	not serious [i]	serious [j]	none detected	⊕⊕⊕⊖ MODERATE
TD 1-year ACS	not serious [a]	serious [k]	not serious [l]	serious [m]	none detected	⊕⊖⊕⊖ LOW

257

Funding

This work was exclusively funded by the University of Bordeaux and INSERM BPH U1219

Disclosures

Frederic Daoud: Biostatistical consulting for several companies including Svelte Medical, Robocath, and Carmat.

Louis Létinier: No disclosure.

Nicholas Moore: No disclosure.

Pierre Coste: No disclosure.

Pasi Karjalainen: No disclosure.

References

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting H, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey Jr DE 1 , Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6; 124(23):e574-651. doi: 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb 28;125(8):e412. Dosage error in article text. PMID: 22064601.

2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29; 127(4):e362-425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. Erratum in: Circulation. 2013 Dec 24;128(25):e481. PMID: 23247304.

3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1. PMID: 23996286.

309 4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS,
310 Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine
311 MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular
312 Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline
313 for the management of patients with non-ST-elevation acute coronary syndromes: a report of the
314 American College of Cardiology/American Heart Association Task Force on Practice
315 Guidelines. Circulation. 2014; 130(25):2354-2394. doi: 10.1161/CIR.0000000000000133. Epub
316 2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text.
317 PMID: 25249586.

318 5. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M,
319 Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J,
320 Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, ESC Scientific
321 Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in
322 patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29; ehaa575.
323 doi: 10.1093/eurheartj/ehaa575. Epub ahead of print. PMID: 32860058.

324 6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP,
325 Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M,
326 Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017
327 ESC Guidelines for the management of acute myocardial infarction in patients presenting with
328 ST-segment elevation: The Task Force for the management of acute myocardial infarction in
329 patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
330 Heart J. 2018; 39(2):119-177. doi: 10.1093/eurheartj/ehx393. PMID: 28886621.

331 7. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS,
332 Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M;
333 PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic
334 and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019; 73(7):741-754. doi:
335 10.1016/j.jacc.2018.11.048. PMID: 30784667.

336 8. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary
337 Intervention Intern Med. 2020; 59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub
338 2019 Oct 7. PMID: 31588089; PMCID: PMC7028427.

339 9. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting
340 stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-714. doi:
341 10.1016/j.jacc.2005.09.047. Epub 2006 Jan 26. PMID: 16487832.

342 10. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R,
343 Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and
344 survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26(7):1473-
345 1480. doi: 10.1161/01.ATV.0000223866.42883.3b. Epub 2006 Apr 27. PMID: 16645158.

346 11. Yazdani SK, Sheehy A, Pacetti S, Rittlemeyer B, Kolodgie FD, Virmani R. Stent Coating
347 Integrity of Durable and Biodegradable Coated Drug Eluting Stents. J Interv Cardiol. 2016;
348 29(5):483-490. doi: 10.1111/joic.12303. Epub 2016 Jun 10. PMID: 27282892.

349 12. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G,
350 Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical
351 Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal
352 hyperplasia. Circulation. 2001; 104(8):928-933. doi: 10.1161/hc3401.093146. PMID: 11514381.

353 13. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric
354 oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci
355 U S A. 2001; 98(7):4202-4208. doi: 10.1073/pnas.071054698. Epub 2001 Mar 20. PMID:
356 11259671; PMCID: PMC31203.

357 14. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T,
358 Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM.
359 Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for
360 coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20):2617-2622. doi:
361 10.1161/CIRCULATIONAHA.104.486647. Epub 2005 May 9. PMID: 15883209.

362 15. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for
363 clinical questions. AMIA Annu Symp Proc. 2006; 2006:359-363. PMID: 17238363; PMCID:
364 PMC1839740.

365 16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions.
366 www.cochrane-handbook.org, version 5.1.0 updated March 2011.

367 17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,
368 Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews
369 and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
370 BMJ. 2009; 339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.

371 18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading
372 quality of evidence and strength of recommendations. Updated October 2013. The GRADE
373 Working Group, 2013. Available from guidelinedevelopment.org/handbook.

374 19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA,
375 Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic
376 Research Consortium. Clinical end points in coronary stent trials: a case for standardized
377 definitions. Circulation. 2007; 115(17):2344-2351. doi:
378 10.1161/CIRCULATIONAHA.106.685313. PMID: 17470709.

379 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-
380 88. doi: 10.1016/0197-2456(86)90046-2. PMID: 3802833.

381 21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect
382 and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97-111. doi:
383 10.1002/jrsm.12. Epub 2010 Nov 21. PMID: 26061376.

384 22. Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J,
385 Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-
386 eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX
387 AMI trial. EuroIntervention. 2008; 4(2):234-241. doi: 10.4244/eijv4i2a42. PMID: 19110789.

388 23. Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W,
389 Airaksinen KE, Karjalainen PP. Five-year clinical outcome of titanium-nitride-oxide-coated
390 bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction:
391 long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013; 168(2):1214-1219. doi:
392 10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3. PMID: 23218575.

393 24. Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M,
394 Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S.
395 Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary
396 revascularization a randomized controlled trial. JACC Cardiovasc Interv. 2011; 4(6):672-682.
397 doi: 10.1016/j.jcin.2011.02.017. PMID: 21700254.

398 25. López-Mínguez JR, Nogales-Asensio JM, Doncel-Vecino LJ, Merchán-Herrera A, Pomar-
399 Domingo F, Martínez-Romero P, Fernández-Díaz JA, Valdesuso-Aguilar R, Moreu-Burgos J,
400 Díaz-Fernández J; members of the TITANIC XV Working Group. A randomized study to
401 compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC
402 XV): 1-year results. Rev Esp Cardiol (Engl Ed). 2014; 67(7):522-530. doi:
403 10.1016/j.rec.2013.10.021. Epub 2014 Apr 3. PMID: 24952391.

404 26. Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo
405 F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated
406 stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE
407 ACS trial. Int J Cardiol. 2016; 222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug
408 1. PMID: 27497110.

409 27. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand
410 J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study
411 investigators. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive
412 stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
413 EuroIntervention. 2012; 8(3):306-315. doi: 10.4244/EIJV8I3A49. PMID: 22829506.

414 28. Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der
415 Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to

416 the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives.
417 Minerva Cardioangiol. 2015; 63(1):21-29. PMID: 25670057.

418 29. Tonino PAL, Pijls NHJ, Collet C, Nammas W, Van der Heyden J, Romppanen H, Kervinen
419 K, Airaksinen JKE, Sia J, Lalmand J, Frambach P, Penaranda AS, De Bruyne B, Karjalainen PP;
420 TIDES-ACS Study Group. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in
421 Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv. 2020;
422 13(14):1697-1705. doi: 10.1016/j.jcin.2020.04.021. PMID: 32703593.

423 30. Savović J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of
424 the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus
425 groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;
426 3:37. doi: 10.1186/2046-4053-3-37. PMID: 24731537; PMCID: PMC4022341.

427 31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ;
428 GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and
429 strength of recommendations. BMJ. 2008; 336(7650):924-926. doi:
430 10.1136/bmj.39489.470347.AD. PMID: 18436948; PMCID: PMC2335261.

431 32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ,
432 Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-
433 Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE
434 guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-
435 1293. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11. PMID: 21839614.

436 33. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster
437 University, 2015 (developed by Evidence Prime, Inc.). Available from https://gdt.gradepro.org

438 34. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential
439 monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997; 18(6):580-593;
440 discussion 661-6. doi: 10.1016/s0197-2456(97)00051-2. PMID: 9408720.

441 35. Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical
442 analysis of dichotomous data for dependent samples. Psychol Bull. 1968; 69(4):269-277. doi:
443 10.1037/h0025667. PMID: 5659656.

444 36. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses
445 in pain using simulations of individual patient data. Pain. 2000; 85(3):415-424. doi:
446 10.1016/s0304-3959(99)00302-4. PMID: 10781914.

447 37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;
448 21(11):1539-1558. doi: 10.1002/sim.1186. PMID: 12111919.

449 38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
450 analyses. BMJ. 2003; 327(7414):557-560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120;
451 PMCID: PMC192859.

452 39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
453 simple, graphical test. BMJ. 1997; 315(7109):629-634. doi: 10.1136/bmj.315.7109.629. PMID:
454 9310563; PMCID: PMC2127453.

455 40. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316(7124):61-66.
456 doi: 10.1136/bmj.316.7124.61. PMID: 9451274; PMCID: PMC2665334.

457 41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other
458 biases. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care:
459 Meta-Analysis in Context. London: BMJ Publishing Group, 2001:189-208.

460 42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses
461 of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443-3457. doi:
462 10.1002/sim.2380. PMID: 16345038.